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Introduction: Newborn Screening (NBS) for Severe
Combined Immunodeﬁciency (SCID) began in 2008 in the
state of Wisconsin. It is predicted that early detection
through NBS will improve hematopoietic cell transplant
(HCT) outcomes for infants diagnosed with SCID. Two
patients were diagnosed by NBS with absent T cell receptor
excision circles (TRECs). The results of their workup and HCT
outcomes are reported here. These two patients emphasize
the dilemmas faced since implementation of NBS SCID
screening.
Results: Both patients were non-dysmorphic, demonstrated
thymic tissue on ultrasound, were negative for maternal
engraftment, and lacked a genetic diagnosis despite exten-
sive expedited gene sequencing. Patient 1 had a classical
SCID phenotype with T-B-NK+ immunophenotype and
markedly diminished PHA response. There was concern for
a radiosensitive form of SCID in patient 1; therefore, a skin
ﬁbroblast line was established. Just prior to transplantation
mild, radiosensitivity was reported. Patient 2 had a non-
classical SCID phenotype with TloB+NK+ immunophenotype
and normal PHA response at birth. Patient 2 was placed in
protective isolation and prophylaxis while extensive workup
ensued. During this observation period, TRECs remained
undetectable and immunophenotype did not change.
Further T cell analysis demonstrated normal spectratyping,
but diminished T cell response to CD3 crosslinking. B cell
functional analysis revealed normal isoagglutinnin titers and
a positive response to killed rabies vaccination. The decision
to transplant was made based on abnormal anti-CD3
response, persistently undetectable TRECs, asymptomatic
low-level CMV detection, and excellent donor source. At 2.5
months of age, patient 1 underwent a 9/10 UCB HCT, and at
16.5 months of age, patient 2 underwent an MSD HCT. Both
patients received RIC conditioning with Busulfan (CSS 400-
600 ng/ml), Fludarabine, and ATG, and CSA with MMF or
MTX for GVHD prophylaxis. Engraftment occurred on days
+28 (patient 1) and +24 (patient 2). Neither patient devel-
oped GVHD. Post-HCT complications for patient 1 includedbacteremia and for patient 2 included transaminitis, mild
SOS, and CMV reactivation. Both patients are alive andwell at
830 (patient 1) and 53 days (patient 2) post-HCT.
Conclusions: These two patients illustrate the successes and
challenges of NBS for SCID. For example, rapid radiosensitive
assays are needed along with widely available and stan-
dardized protocols for assessing B cell function in infants.
Large, multicenter, prospective trials are needed to deﬁne
criteria for HCT, optimal conditioning regimen, and age for
HCT in clinically well newborns lacking a genetic diagnosis.289
Recovery of Lymphocyte Function May Predict Risk of
Leukemic Relapse in Pediatric Patients Undergoing
Allogeneic Stem Cell Transplant
Justin T. Wahlstrom 1, Patricia Murphy 2, Biljana Horn 1,
Morton J. Cowan 1, Christopher C. Dvorak 1. 1 Pediatric Allergy
Immunology and Blood and Marrow Transplant Division, UCSF
Benioff Children's Hospital, San Francisco, CA; 2 Pediatrics,
UCSF Children's Hospital, San Francisco, CA
Delayed immune reconstitution after allogeneic trans-
plant for pediatric acute leukemia has been implicated by
some studies as a risk for leukemic relapse. However, results
regarding the speciﬁc laboratory parameters of interest have
been conﬂicting. We initiated a retrospective review of 97
pediatric patients who underwent allogeneic stem cell
transplantation for ALL, AML or JMML between the years of
2000 and 2010. We collected available clinical outcomes data
which included lymphocyte subset (CD3, CD4, CD8, CD19,
CD16/56) recovery at 90 and 180 days, proliferative response
of CD3 T cells to phytohemagglutinin (PHA) at 90 and 180
days, and donor CD3 chimerism at 30 days post-transplant.
Median cutoffs associated with immune reconstitution that
were used for data analysis included a CD4 count >200, CD8
count >200, and PHA >30% of lower limit of normal control.
Full donor CD3 chimerismwas deﬁned as no evidence of host
DNA down to a sensitivity of 1%. Data for immunophenotype
was available for 71 patients; CD3 chimerism was available
for 50 patients, and PHA responses were available for 47
patients.
No signiﬁcant difference in CD4 or CD8 Tcell recoverywas
detected between relapse and non-relapse patients.
However, a higher rate of relapse was observed in patients
with a PHA response <30% within the ﬁrst 180 days (4/7, 5-
year RFS 42.8%), compared to those with PHA >30% (5/40, 5-
year RFS 84.8%, P ¼ .02). In the subset of patients for whom
both PHA and chimerism datawere available, a higher rate of
relapse was observed in patients with either mixed CD3
chimerism or poor PHA response (8/27), compared to those
who recovered both full donor CD3 chimerism and CD3 PHA
response >30% (0/7, P ¼ .1).
Historically, tailoring of immunotherapy post-transplant
has focused on the treatment of graft-versus-host disease.
With the availability of clinical tools to better predict
leukemic relapse post-transplant, further intervention (such
as withdrawal of immunosuppression and/or DLI) may be
implemented safely and effectively for those who require it.
This preliminary data indicates that PHA response is a clini-
cally accessible indicator of immune reconstitution that may
be an important variable to consider when predicting
a patient's risk for relapse. Further study is needed to
determine the degree to which PHA response might affect
speciﬁc groups of patients.
